Table 1.
Features of patients with post-surgical intra-abdominal infections
| Parameter | MT Group | CT Group |
|---|---|---|
| Number of patients | 128 | 163 |
| Sex (n, %) | ||
| Male | 98 (76.56) | 104 (63.80) |
| Female | 30 (23.44) | 45 (36.20) |
| Age (years) | 56.10 ± 7.67 | 56.30 ± 7.43 |
| Underlying diseases, n (%) | ||
| Diabetes | 10 (7.81) | 13 (7.98) |
| CKD | 2 (1.56) | 2 (1.23) |
| CHF | 0 | 3 (1.84) |
| COPD | 10 (7.81) | 5 (3.07) |
| Site of tumor, n (%) | ||
| Liver | 24 (18.75) | 18 (11.04) |
| Biliary tract | 38 (29.69) | 39 (23.93) |
| Gastrointestinal tract | 50 (39.06) | 94 (57.67) |
| Pancreas | 16 (12.50) | 12 (7.36) |
| Responsible pathogens, n (%) | ||
| Enterococcus. spp. | 11 (8.59) | 29 (17.79) |
| Escherichia coli (total) | 38 (29.69) | 60 (36.81) |
| Escherichia coli (CRO) | 8 (6.25) | 6 (3.68) |
| Klebsiella spp. (total) | 26 (20.31) | 32 (19.63) |
| Klebsiella spp. (CRO) | 6 (4.69) | 10 (6.13) |
| Enterobacter cloacae (total) | 15 (11.72) | 9 (5.52) |
| Enterobacter cloacae (CRO) | 4 (3.13) | 5 (3.07) |
| Acinetobacter baumannii (CRO) | 10 (7.81) | 18 (11.04) |
| other bacteria | 28 (21.88) | 15 (9.20) |
| Antibiotic combination, n (%) | ||
| Ceftazidime | N/A | 16 (9.82) |
| Piperacillin/tazobactam | N/A | 48 (29.45) |
| Cefoperazone/sulbactam | N/A | 89 (54.60) |
| Ceftriaxone | N/A | 4 (2.45) |
| Cefoxitin | N/A | 6 (3.68) |
| Parameters before tigecycline medication | ||
| Temperature (℃) | 38.31 ± 0.47 | 38.42 ± 0.36 |
| CRP (mg/L) | 77.14 ± 20.18 | 81.25 ± 36.71 |
| PCT (ng/mL) | 2.50 ± 1.06 | 2.48 ± 0.64 |
| White Blood Cell (*109/L) | 18.12 ± 3.77 | 21.69 ± 2.60 |
| Hospital length of stay (days) | 13.43 ± 5.12 | 15.76 ± 8.25 |
MT Group: tigecycline monotherapy; CT Group: tigecycline plus β-lactam antibiotics; CRO, Carbapenem-resistant organisms protein; CRP, C-reactive protein; PCT: Procalcitonin; CHF: Congestive heart failure; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; CRO: Carbapenem-resistant organisms